Associate professor Iman Ahmad, PhD, recently published, “Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment,” in Translational Oncology.
Dr. Ahmad co-authored the publication with a graduate student from the College of Medicine, marking a successful co-supervision and a strong example of campus-wide collaboration.
The study explores the therapeutic potential of Heme oxygenase-1 (HO-1) inhibition in prostate cancer (PC), particularly in combination with Docetaxel. By reducing tumor proliferation, enhancing apoptosis, and modulating the tumor immune microenvironment, HO-1 inhibitors can significantly improve treatment responses and overcome chemoresistance. These results pave the way for further preclinical investigation of HO-1 inhibitors as part of combination therapies for advanced PC.
This work reflects the value of interdisciplinary partnerships and mentorship in advancing impactful research.